UNSPSC 51171927: Acetoxolone

This classification denotes a peptic ulcer drug with the molecular formula C32H48O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CWW961Q19K, chemically known as acetylglycyrrhetic acid or (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-acetoxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid, and which bears US NIH Compound Identifier 94320. European Medicines Agency schedules acetoxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21866.

As of Q4 2014, ACETOXOLONE remains the US FDA Preferred Term for this commodity. Acetoxolone bears US NLM identifiers UMLS ID C0050521 and NCI Concept Code C98247. SMILES: CC(=O)OC1CCC2(C(C1(C)C)CCC3(C2C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C.

UNSPSC 51171927 Acetoxolone is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little direct relevance to acetoxolone itself. Instead, the code appears to tag a broader pharmaceutical and drug-testing procurement landscape. State and local governments soliciting under this code are acquiring drug-testing services, generic pharmaceuticals through cooperative purchasing, and prescription fulfillment programs. The mix of issuing bodies includes county-level community corrections departments, state health and human services agencies, and multistate cooperative purchasing alliances that serve state departments and local government facilities. The work scopes range from offender specimen collection and drug screening with laboratory confirmation (immunoassay and LC/MS/MS or GC/MS methods) to generic pharmaceutical supply agreements and exploratory pharmacy benefit innovation programs.

Recent activity spans Texas and Minnesota. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a July 23, 2026 response deadline; the estimated contract value is $600,000, the term is two years commencing September 1, 2026 with three optional one-year renewals, and the county will award to one or more responsible contractors based on vendor understanding, firm qualifications, client references, and cost. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon; the RFP requires vendors to work through three authorized wholesalers and emphasizes price competitiveness (75 percent evaluation weight) alongside cGMP certification, Drug Supply Chain Security Act compliance, and EDI capability. The Texas Health and Human Services Commission also posted Request for Information HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a preliminary market intelligence phase ahead of formal procurement specifications.